Equities research analysts expect that Avid Bioservices Inc (NASDAQ:CDMO) will post earnings per share of ($0.09) for the current fiscal quarter, according to Zacks. Two analysts have provided estimates for Avid Bioservices’ earnings, with the highest EPS estimate coming in at ($0.01) and the lowest estimate coming in at ($0.16). Avid Bioservices posted earnings of ($0.06) per share in the same quarter last year, which would indicate a negative year-over-year growth rate of 50%. The business is expected to issue its next quarterly earnings report on Monday, September 10th.

According to Zacks, analysts expect that Avid Bioservices will report full-year earnings of ($0.20) per share for the current financial year, with EPS estimates ranging from ($0.33) to ($0.03). For the next financial year, analysts expect that the company will report earnings of $0.02 per share, with EPS estimates ranging from ($0.07) to $0.14. Zacks Investment Research’s EPS averages are an average based on a survey of sell-side research analysts that follow Avid Bioservices.

Avid Bioservices (NASDAQ:CDMO) last issued its quarterly earnings results on Monday, July 16th. The biopharmaceutical company reported $0.05 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.15) by $0.20. The business had revenue of $6.94 million during the quarter, compared to analysts’ expectations of $6.51 million. Avid Bioservices had a negative return on equity of 58.67% and a negative net margin of 40.68%.

CDMO has been the subject of several recent research reports. HC Wainwright initiated coverage on Avid Bioservices in a research note on Thursday, May 24th. They issued a “buy” rating and a $5.00 price target for the company. Janney Montgomery Scott initiated coverage on Avid Bioservices in a research note on Monday, June 25th. They issued a “buy” rating and a $10.00 price target for the company. ValuEngine upgraded Avid Bioservices from a “sell” rating to a “hold” rating in a research note on Friday, June 1st. Finally, Zacks Investment Research cut Avid Bioservices from a “hold” rating to a “sell” rating in a research note on Thursday, July 19th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and five have issued a buy rating to the stock. Avid Bioservices has an average rating of “Buy” and a consensus target price of $7.50.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. BlackRock Inc. lifted its stake in Avid Bioservices by 329.6% during the second quarter. BlackRock Inc. now owns 3,261,288 shares of the biopharmaceutical company’s stock worth $12,784,000 after purchasing an additional 2,502,164 shares during the last quarter. Bandera Partners LLC bought a new stake in Avid Bioservices during the first quarter worth $2,984,000. CVI Holdings LLC bought a new stake in Avid Bioservices during the first quarter worth $1,729,000. Schwartz Investment Counsel Inc. bought a new stake in Avid Bioservices during the first quarter worth $1,387,000. Finally, Wells Fargo & Company MN bought a new stake in Avid Bioservices during the first quarter worth $644,000. Hedge funds and other institutional investors own 18.87% of the company’s stock.

Shares of CDMO stock opened at $5.49 on Monday. The company has a market capitalization of $319.70 million, a P/E ratio of -10.98 and a beta of 2.19. Avid Bioservices has a 1 year low of $2.24 and a 1 year high of $6.57.

About Avid Bioservices

Avid Bioservices, Inc operates as a contract development and manufacturing organization focusing on the development and cGMP manufacture of biopharmaceutical products derived from mammalian cell culture. It provides a range of process development, and cGMP clinical and commercial manufacturing services for the biotechnology and biopharmaceutical industries.

Recommended Story: How to Invest in Growth Stocks

Get a free copy of the Zacks research report on Avid Bioservices (CDMO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Avid Bioservices (NASDAQ:CDMO)

Receive News & Ratings for Avid Bioservices Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avid Bioservices and related companies with MarketBeat.com's FREE daily email newsletter.